Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Anacor Pharmaceuticals, Inc. | a14-21290_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 22, 2014
Anacor Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-34973 |
|
25-1854385 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
1020 East Meadow Circle
Palo Alto, CA 94303-4230
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (650) 543-7500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On September 22, 2014, Anacor Pharmaceuticals, Inc. issued a press release announcing the commercial launch of KERYDINTM (tavaborole) topical solution, 5% in the United States. A copy of such press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit |
|
Description |
99.1 |
|
Press Release issued September 22, 2014 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ANACOR PHARMACEUTICALS, INC. | ||
|
| ||
|
|
| |
|
By: |
/s/ Ryan T. Sullivan | |
|
|
Name: |
Ryan T. Sullivan |
|
|
Title: |
Senior Vice President and General Counsel |
Date: September 22, 2014